Objective: Saphenous vein is the conduit of choice for bypass grafting. Saphenous vein grafts have poor long-term patency rates because of intimal hyperplasia (IH) and subsequent accelerated atherosclerosis. One of the primary triggers of IH is endothelial injury resulting from excessive dilation of the vein after exposure to arterial pressures. Photochemical tissue passivation (PTP) is a technology that cross-links adventitial collagen by a light-activated process, which limits dilation by improving vessel compliance. The objective of this study was to investigate whether PTP limits the development of IH in a rodent venous interposition graft model. Methods: PTP is accomplished by coating venous adventitia with a photosensitizing dye and exposing it to light. To assess the degree of collagen cross-linking after PTP treatment, a biodegradation assay was performed. Venous interposition grafts were placed in the femoral artery of Sprague-Dawley rats. Rats were euthanized after 4 weeks, and intimal thickness was measured histologically. Vein dilation at the time of the initial procedure was also measured. Results: Time to digestion was 63 6 7 minutes for controls, 101 6 2.4 minutes for rose bengal (RB), and 300 6 0 minutes for PTP (P < .001 PTP vs control). A total of 37 animals underwent the procedure: 12 PTP, 12 RB only, and 13 untreated controls. Dilation of the graft after clamp release was 99% for control, 65% for RB only, and 19% for PTP-treated (P < .001 PTP vs control). Intimal thickness was 77 6 59 mm in controls, 60 6 27 mm in RB only, and 33 6 28 mm in PTP-treated grafts. There was a statistically significant 57% reduction in intimal thickness after treatment with PTP compared with untreated controls (P [ .03). Conclusions: PTP treatment of venous interposition grafts in a rat model resulted in significant collagen cross-linking, decreased vessel compliance, and significant reduction in IH. (J Vasc Surg 2017;65:190-6.) Clinical Relevance: Long-term patency rates are poor after coronary or lower extremity bypass with autologous vein. This is largely due to intimal hyperplasia (IH), superimposed accelerated atherosclerosis, and graft thrombosis. A key inciting event is graft overdistention and endothelial denudation after exposure to arterial pressure. Limiting overdistention by external mechanical support has been shown to reduce IH. Photochemical tissue passivation involves cross-linking adventitial collagen, a novel approach to limit overdistention of the vein without an external prosthesis. Photochemical tissue passivation resulted in a 57% reduction of IH. Minimizing vein graft IH would greatly improve long-term outcomes after arterial bypass.
In the United States, approximately 82 million people live with cardiovascular disease. Cardiovascular disease continues to be the leading cause of death in the United States, accounting for approximately 17% of yearly deaths. Despite the recent advances in endovascular surgery, many patients continue to benefit from open lower extremity revascularization procedures. Open surgery is the only option for patients with complete superficial femoral artery or popliteal occlusion. 1 The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial showed superior long-term patency rates of open bypass compared with angioplasty for infrainguinal disease, making it the procedure of choice for patients with a life expectancy of >2 years who have available autologous veins. 2 The literature also suggests that diabetics with critical limb ischemia and a life expectancy of >2 years are better served with open revascularization using autologous vein. 3 Therefore, bypass using autologous vein remains the "gold standard" for infrainguinal disease. 1 For patients with coronary disease, recent literature has also shown an unequivocal benefit of coronary artery bypass grafting (CABG) compared with percutaneous coronary interventions. 4, 5 In patients with multivessel disease, there is a 27% reduction in mortality after CABG compared with percutaneous coronary intervention. 4 Moreover, patients who undergo CABG have a significantly lower number of revascularizations, resulting in lower longterm health care costs. 4 The recently published Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) study also suggests a reduction in morbidity and mortality after CABG in diabetic patients. 5 The aging population in combination with these emerging data is likely to result in an increasing number of open coronary revascularization procedures.
Autologous veins are the gold standard conduit for coronary bypass and peripheral arterial bypass because of their availability, ease of use, and lower infectious risk compared with synthetic grafts. In 2010, 395,000 CABG procedures were performed in the United States, 6 with saphenous vein graft (SVG) being the most commonly used conduit for coronary revascularization. However, the effectiveness of SVGs is limited by poor long-term patency rates compared with arterial grafts. When left internal mammary artery grafts are used for coronary revascularization, 90% remain open after 10 years. Conversely, only 50% of SVGs remain patent, 7 with 50% of those having a significant atherosclerotic burden by angiography. 8 Venous grafts for peripheral arterial reconstruction suffer from similar shortcomings. [9] [10] [11] When SVG is used for lower extremity infragenicular bypass, patency rates approach 25% to 55% at 5 years after surgery.
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The poor long-term outcomes of venous grafts are due to the luminal narrowing that results from intimal hyperplasia (IH), medial thickening, and subsequent superimposed accelerated atherosclerosis. 7, 13 One of the primary triggers that leads to the development of IH is endothelial injury, early denudation, and the inflammatory cascade that ensues after exposure of the venous tissue to surgical trauma, longitudinal wall (shear) stress, and increased arterial pressure.
14 Mechanical trauma can be addressed only by meticulous "no-touch" surgical technique; however, limiting the acute dilation of the graft can be achieved through a variety of methods. External mechanical support may limit dilation and has been shown to reduce the degree of IH. 10, 15, 16 To date, mechanical support is achieved through the use of external sheaths, which are applied over the vein graft before implantation and exposure to arterial pressure. 10, 15, 16 External sheaths are cumbersome and can lead to technical difficulties. 16 Furthermore, the use of a foreign body yields a potential risk of erosion and infection.
Photochemical tissue passivation (PTP) is a technology that cross-links surface proteins (ie, adventitial collagen) by a light-activated process. Tissue adventitia is coated with a photosensitizing dye, rose bengal (RB), which is activated with a low-energy visible light. Collagen cross-linking strengthens the venous conduit, decreasing its compliance to more resemble that of an artery. Despite this decrease in compliance, the pliability remains uncompromised. Photochemical cross-linking has been used successfully for sutureless skin closure, 17 sutureless microvascular anastomoses, 18 and bonding of human amniotic membrane over corneal defects without sutures. 19 PTP does not increase operating time, does not alter the technical difficulty of the procedure, and eliminates the risks associated with prosthetic external sheaths.
These experiments were designed to test the hypothesis that PTP treatment can cross-link adventitial collagen in vein grafts and limit the development of IH once the veins are arterialized.
METHODS
All animal experimentation was done under the approval of the Institutional Animal Care and Use Committee.
Biodegradation assay. To quantitatively demonstrate collagen cross-linking in an in vitro setting, epigastric vein was harvested from three rats under an operating microscope using a strict no-touch technique. The veins were cut into 2.5-mm segments, resulting in 21 samples. A third of the samples were treated with PTP, a third were coated with RB without exposure to the light, and a third served as an untreated controls. The PTP treatment was achieved by coating the adventitia with 0.1% (w/v) RB and exposing it to a fluence of 25 J/cm 2 using a 532-nm light. The samples were then immersed in 0.1% (w/v in phosphatebuffered saline) collagenase solution (Sigma-Aldrich, St. Louis, Mo) and placed in an incubator at 37 C. Time to complete digestion was measured.
Venous interposition grafting. In vivo testing was done through an animal model consisting of a venous interposition graft in the femoral artery of SpragueDawley rats. A segment of reversed superficial epigastric vein was used as an interposition graft.
A total of 37 animals underwent the procedure: 12 vein grafts were treated with PTP; 12 vein grafts were coated with RB but did not undergo light treatment; and 13 vein grafts served as untreated controls (no RB, no light). Animals were euthanized 4 weeks after the procedure. Two additional animals (one treated with PTP and one untreated control) underwent the procedure but were euthanized after 1 hour for histologic analysis of the vein graft architecture after clamp release.
Description of the procedure. Rats were anesthetized with 50 mg/kg of pentobarbital intraperitoneally. The right groin was shaved and prepared with povidoneiodine (Betadine) solution. A 2-cm incision was made along the groin crease. After medial reflection of the inguinal fat pad, the epigastric vein was harvested using meticulous atraumatic technique. The vein was flushed with heparinized saline and stored in a Hanks balanced salt solution containing papaverine and heparin (2000 U of heparin and 120 mg of papaverine in 250 mL of Hanks balanced salt solution). After exposure and clamping of the femoral artery, a 0.3-cm segment of artery was resected and a 1-cm segment of vein was placed as an interposition graft in a reversed manner. PTP of the venous graft was performed in the experimental group before implantation into the femoral artery. This was done by placing the vein graft on moist gauze, coating it with 0.1% w/v RB using a cotton-tipped applicator, and illuminating it with 532-nm light at 500 mW/cm 2 , resulting in a treatment fluence of 25 J/cm 2 . The graft was then turned over and the other side treated in the same manner. Both anastomoses were then hand sewn using six to eight interrupted 10-0 nylon stitches. The vein graft diameter was measured with calipers before and after release of the arterial clamps to compare the compliance of the grafts. The diameter was measured in the midportion of the graft, away from the anastomoses, to avoid the areas manipulated during the procedure. The percentage dilation was then calculated as [(final diameter À initial diameter)/initial diameter] Â 100. The inguinal fat pad was then draped back over the vessels, tacking it down to the underlying muscles with interrupted Vicryl stitches. The skin was closed in two layers using absorbable suture. The animals were allowed to recover and received postoperative analgesia for 72 hours with buprenorphine 0.01 mg/kg intramuscularly, twice daily.
Rats were euthanized 4 weeks later with a lethal dose of pentobarbital (100 mg/kg intraperitoneally). Before euthanasia, the animals were anesthetized, and the vein grafts were dissected while the animal was still alive. This was done to ensure graft patency at the time of harvest. The grafts were perfusion fixed at 100 mm Hg of pressure with 4% paraformaldehyde, then placed in 4% paraformaldehyde for 24 hours before preparation for histologic analysis.
The fixed harvested grafts were paraffin embedded for cross-sectional histologic evaluation. Each vein graft was divided in the middle and embedded with both cross sections of the midportion of the graft facing the edge of the block to be cut by the microtome. Four 5-mm cuts of the block were placed on each slide, so that eight cross sections of the midportion of the graft could be evaluated per slide. Slides were prepared for light microscopy using a Verhoeff-van Gieson elastin stain. IH was measured by choosing the maximal intimal thickness out of two slides, each containing eight cross sections of the midportion of the graft. The reference points for measurement were the internal elastic lamina and the vessel lumen.
Statistical analysis. A variance components model showed no variance attributable to the animals; therefore, the data were treated as independent, and group comparisons were made by the Mann-Whitney rank sum test. A P value of .05 was considered statistically significant. Data analysis was performed using the StatPlus statistical software (AnalystSoft, Inc, Vancouver, BC, Canada).
RESULTS
Biodegradation assay. The digestion time was 63 6 7 minutes for controls (n ¼ 7), 101 6 2.4 minutes for the RB-only group (n ¼ 7), and 300 6 0 minutes for the PTP-treated group (n ¼ 7). The experiments were terminated after 5 hours, at which time none of the treated samples were fully digested in contrast to the untreated samples and the RB-only samples, which were all fully digested. P values were < .01 in comparing all groups (PTP vs control, PTP vs RB, control vs RB).
Venous interposition grafting. Average operative time was 2 hours. Additional operative time for the PTP group was 5 minutes on average. There were three instances of wound dehiscence between postoperative days 1 and 2, one in the control group and two in the experimental group. These wounds were irrigated and resutured. None of the grafts were exposed. There were no wound infections. After 4 weeks, 100% of the vein grafts were patent. There were no pseudoaneurysms or aneurysmal dilation of the grafts.
To quantitatively assess the compliance of the vein grafts, the vein graft diameter was measured before and after release of the arterial clamps at the time of the initial procedure. The control and RB-only groups exhibited a statistically significant increased dilation compared with the PTP group (control vs PTP, P < .001; RB-only vs PTP, P ¼ .02). Dilation of the graft after clamp release was measured to be 99% 6 34% for untreated controls, 65% 6 33% for RB-only, and 19% 6 21% for grafts treated with PTP (Figs 1 and 2) .
Two additional animals (one treated with PTP, one untreated control) were euthanized 1 hour after implantation of the vein graft to assess the amount of acute histologic damage after the release of the arterial clamps. A representative cross section of each is shown in Fig 3. The vein graft treated with PTP had preserved normal architecture, whereas the untreated control vein (no RB, no PTP) was dilated and thinned out and had loss of endothelial integrity.
Histologic cross sections of the midportion of the graft were analyzed using light microscopy. All grafts were re-endothelialized at the 1-month time point.
Intimal thickness was 77 6 59 mm in untreated controls, 60 6 27 mm in RB-only grafts, and 33 6 28 mm in PTPtreated grafts. There was statistical significance between untreated and PTP-treated grafts (P ¼ .03). This represents a 57% reduction in intimal thickness in the group treated with PTP. There was also statistical significance between RB-only and PTP-treated grafts (P ¼ .04). There was no statistically significant significance between the untreated control grafts and the RB-only grafts (P ¼ .28; Figs 4 and 5) .
DISCUSSION
These experiments demonstrate the efficacy of PTP therapy in modulating the structural integrity of vein grafts using in vitro and in vivo techniques. Substantial in vitro evidence (biodegradation assay) is provided to indicate that PTP treatment promptly cross-linked collagen as the degradation times for the treated vein grafts were at least five times greater than for the untreated vein grafts. A collagenase degradation assay is a standard methodology for investigating the extent of collagen cross-linking in tissue. This in vitro evidence correlated with preservation of vein graft architecture immediately after implantation as there was a significant reduction in acute overdilation of PTP-treated vein grafts compared with untreated vein grafts (Fig 1) . Furthermore, histologic analysis of the grafts 1 hour after implantation showed evidence of preserved integrity of the intima and the media of the treated grafts (Fig 3) . This rapid alteration of the structural integrity of the vein is critically important in halting the subsequent development of IH and vein graft failure. In a recent analysis of vein graft failure, 14 early denudation of endothelium due to surgical trauma, longitudinal wall (shear) stress, and increased arterial pressure are the primary triggers toward the development of IH and decreased vein graft patency.
Whereas the vein graft re-endothelializes during the next 1 to 2 weeks, the new endothelium is dysfunctional. As an adaptive injury response to the increased wall stress, intima becomes hyperplastic and forms a neointima, which resembles a combined intima-media layer of a normal artery; this neointima is predominantly formed by vascular smooth muscle cells. A critical determinant of vessel patency is re-endothelialization and neointima formation. Subsequently, the neointima thickens by migration of vascular smooth muscle cells and accumulation of extracellular matrix (mainly collagen formation). Thus, the finding in this report that PTP-treated veins are able to resist chemical degradation in vitro and structural deformation in vivo shortly after treatment suggests that this approach will protect venous conduits from injury as soon as the grafts are implanted in the arterial system.
The effect of PTP treatment on vein graft morphology when the grafts were explanted at 1 month was equally important. PTP treatment halted the development of IH in treated vein grafts at 1 month after implantation. This is an important observation because vein graft remodeling is a chronic inflammatory process that results in the release of cytokines and other proinflammatory agents from macrophages and smooth muscle cells. This in turn creates an atherogenic environment that represents the substrate on which accelerated atherosclerosis develops. Whereas no evidence of atherosclerosis was noted in either the treated or untreated vein segments of these normotensive nonhyperlipidemic rats, there was no evidence of thickened or disrupted intima in the PTP-treated rats after 1 month of implantation. The absence of thickened or disrupted intima (which is a precursor to development of atheroma) in the PTP-treated rats suggests that they are likely to be resistant to the development of vein graft atherogenesis. PTP-treated veins did undergo a degree of adaptive dilation without the IH typically seen in vein grafts. Medial thickening was observed in both treated and untreated vein grafts. This is similar to the work done with biodegradable external stents by Vijayan et al, in which they reported that the reduction in IH lasts after 6 months despite the stent's being fully biodegraded. 10 We hypothesize that it is the prevention of the initial insult that reduces the ensuing inflammatory response and allows the vein graft to undergo a slow adaptive process without the formation of excessive intimal thickening.
There is a substantial amount of data to suggest that methods modulating the structural characteristics of arterial vein graft will decrease IH and decrease vein graft failure. External mechanical support has received significant attention from the research community with good experimental data. Mehta et al published a report in Nature Medicine of six pigs undergoing carotid artery interposition grafts with saphenous vein. 15 The experimental group had the grafts covered with a polyester stent, which resulted in 92% reduction of intimal thickness after 6 months. This work was replicated with the same animal model by Vijayan et al but using a biodegradable polyglactin external sheath, which is hydrolyzed by 90 days. 10 This resulted in reduction of IH beyond the life span of the stent, 70% and 72% after 1 month and 6 months, respectively. In yet another study, Moodley et al 16 evaluated the approach of using externally supported vein grafts in a CABG model using nonhuman primates (chacma baboons). They performed CABG on 18 baboons, six of which had SVG covered with a knitted nitinol mesh. They reported 58.5% reduction in intimal thickness at 180 days, showing that the concept holds true for coronary revascularization as well. However, these authors identified technical problems with externally supported vein grafts that would undoubtedly complicate the ability to use the technology in humans. This illustrates the problem with external support by a mechanical sheath; it is a cumbersome method with high risk for technical errors and a theoretical risk of long-term problems, such as infection or erosion, given that a foreign body surrounds the graft. From a conceptual standpoint, the experiments with externally supported vein grafts reinforce the need to have an approach that limits the initial intimal injury induced by excessive dilation to achieve long-lasting reduction of IH.
In contrast to structural alterations to the vein graft, there have been many pharmacologic approaches to reduce the adverse remodeling of vein grafts, which leads to reduced patency. Lipid control with statins is the only therapy shown to marginally improve long-term angiographic outcomes. 20, 21 Experimentally, rapamycin has sparked the interest of many researchers, given its well-established role in reduction of long-term neointimal hyperplasia within coronary stents. 22, 23 However, rapamycin has shown limited success in animal studies of vein grafting. 24, 25 Despite aggressive use of antiplatelet and antilipid agents, IH and vein graft failure remain significant ongoing clinical problems.
Use of PTP as an approach to immediately modulate the structural integrity of vein grafts offers a simple, fast, and inexpensive method without the burden of external sheathing.
PTP is a light-activated process without a thermal component. 17 There is precedence for using this technology because photochemical cross-linking has been used successfully for sutureless skin closure, 17 sutureless microvascular anastomoses, 18 and bonding of human amniotic membrane over corneal defects without sutures. 19 PTP reinforces adventitial collagen through covalent cross-linking. RB strongly adheres to collagen, which restricts diffusion beyond the vessel's adventitia. Covalent cross-linking of adventitial collagen does not mediate a body response at the cellular or molecular level. In animal and human studies, PTP has not been shown to have any toxicity or deleterious cellular effects. 18, 19, 26, 27 In these studies, we demonstrated objective crosslinking in vitro with a 350% increase in digestion time by collagenase solution. In vivo, we demonstrated that crosslinking of adventitial collagen with PTP strengthens venous grafts (ie, decreases their compliance), reducing the degree of dilation at the time of exposure to arterial pressure.
In our animal model, PTP of the venous grafts before implantation led to a statistically significant 57% reduction of intimal hyperplasia after 4 weeks and did not have an adverse effect on graft patency, as 100% of the grafts were patent.
The group that was treated with RB-only (no light treatment) showed a small, nonsignificant decrease in intimal thickness at 4 weeks. It also showed a longer degradation time than untreated controls. The nonsignificant decrease in intimal thickness was possibly due to a mild degree of cross-linking induced by the microscope light during the harvest and preparation of the vein. The light bulbs in our microscope emit some light in the absorbance spectrum of RB (green light around 532 nm). Therefore, after RB application, the vein graft is exposed to a small amount of energy in the RB absorbance spectrum. This could result in some excitation and collagen cross-linking. The degradation study showed a mild increase in time to digestion of RB vs controls. However, the samples treated with light (PTP group) showed much more robust cross-linking (lack of digestion after 300 minutes). The slight increase in degradation time of the RB-only group compared with control was possibly due to the binding of RB to collagen, which may inhibit or reduce collagenase's access to its target site for enzymatic cleavage. The in vivo model showed a statistically significant difference in IH between RB-only and PTP-treated grafts (P ¼ .04).
CONCLUSIONS
PTP is a novel, simple, and effective approach to dramatically reduce intimal hyperplasia in arterialized venous grafts. PTP does not increase operating time, does not alter the technical difficulty of the procedure, and eliminates the risks associated with prosthetic external sheaths. A study to elucidate the acute biologic effects of PTP treatment on vein grafts as well as an analysis of the efficacy of PTP in a larger animal model of arterialized vein grafts is warranted by these encouraging results.
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